Exenatide: An incretin mimetic for the treatment of type 2 diabetes mellitus
- 1 May 2006
- journal article
- review article
- Published by Elsevier in Clinical Therapeutics
- Vol. 28 (5) , 652-665
- https://doi.org/10.1016/j.clinthera.2006.05.006
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Glucagon-like peptide 1 and its derivatives in the treatment of diabetesRegulatory Peptides, 2005
- ExenatideDrugs, 2005
- Effect of Intravenous Infusion of Exenatide (Synthetic Exendin-4) on Glucose-Dependent Insulin Secretion and Counterregulation During HypoglycemiaDiabetes, 2004
- Poor Control of Risk Factors for Vascular Disease Among Adults With Previously Diagnosed DiabetesJAMA, 2004
- Enhancing Incretin Action for the Treatment of Type 2 DiabetesDiabetes Care, 2003
- Diabetes treatments get sweet help from natureNature Medicine, 2003
- Synthetic Exendin-4 (Exenatide) Significantly Reduces Postprandial and Fasting Plasma Glucose in Subjects with Type 2 DiabetesJournal of Clinical Endocrinology & Metabolism, 2003
- Economic Costs of Diabetes in the U.S. in 2002Diabetes Care, 2003
- The Insulinotropic Effect of Acute Exendin-4 Administered to Humans: Comparison of Nondiabetic State to Type 2 DiabetesJournal of Clinical Endocrinology & Metabolism, 2002
- Bioactive peptides from lizard venomsRegulatory Peptides, 1996